ABVC (abvcpharma.com) Enterprise Value-to-Revenue Ratio

Public company logo of abvcpharma.com (ABVC)

The financial discipline of ABVC BioPharma (ABVC) management raises questions, which impacts the bottom line. The price-to-sales ratio demonstrates volatility, and the 0.00 mark reflects the latest data. Revenues are based on the licensing of plant-based developments for cancer therapy and neurology. However, stringent FDA requirements for antidepressants create risks of delays and render payback periods uncertain.

ABVC BioPharma, Inc (ABVC) Company Value to Revenue: for the period 11/23/2025 - 11/19/2026

ABVC BioPharma, Inc - analytical breakdowns and key metrics (ABVC)

- share price and expert price forecast:
- business market valuation indicators:
Initial company analysis:ABVC, abvcpharma.com
Flagship merchandise of ABVC BioPharma Inc

The market values ABVC BioPharma through the lens of licensing agreement potential, which allows the company to avoid direct price competition in the oncology and psychiatry sectors. An analysis of the EV/Sales ratio reveals the enterprise value relative to revenue, accounting for net debt, helping investors distinguish fundamental undervaluation from a systemic crisis and identify entry points during institutional buy-ins of the asset.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio